Any individual considering retatrutide should do so only within the context of an approved clinical trial or under direct medical supervision
Currently, the buzz is surrounding Retatrutide, an experimental triple-agonist drug
GLP analogs (other than lixisenatide) are contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a family history of medullary thyroid carcinoma
Adding B12 helps counteract low energy levels, reducing feelings of sluggishness and supporting daily activities
This guidance applies to all retatrutide use, but it is especially important for alternative dosing schedules
Important advice for users of GLP-1 medications and weight-loss peptides You must notify your anaesthetist or the hospital pre-admission clinic as soon as possible if you use any GLP-1 diabetic or weight-loss medications, including: Ozempic / Wegovy (Semaglutide) Mounjaro (Tirzepatide) Trulicity (Dulaglutide) Victoza / Saxenda (Liraglutide) You must tell your anaesthetist if you use peptide products for weight loss, in particular products that are labelled: Retatrutide, Reta, R-10, R-20